22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc.’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow Capital,...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Altor BioScience, NantKwest deal

Altor and NantKwest partnered to co-develop cancer therapies using Altor’s ALT-803 and ALT-801 in combination with NantKwest’s natural killer (NK) cell therapy platforms. ALT-803, an IL-15 mutant agonist complexed to an Fc fusion...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

ALT-801: Phase Ib/II data

Data from 34 chemotherapy-refractory patients in the dose-escalation and expansion stages of an open-label, U.S. Phase Ib/II trial showed that 0.06 mg/kg IV ALT-801 plus gemcitabine with or without cisplatin led to an ORR of...
07:00 , Apr 19, 2012 |  BC Innovations  |  Cover Story

A super kind of cytokine

Stanford and Zurich researchers have engineered a variant of IL-2 that shows a better antitumor response in mice than wild-type IL-2.1 The new IL-2 superkine variant, dubbed super-2, has been licensed by Teva Pharmaceutical Industries...
08:00 , Jan 24, 2011 |  BioCentury  |  Finance

Less VC, more SBIR

Altor BioScience Corp. and its investors have structured a financing strategy that keeps the company eligible for Small Business Innovation Research grants, thus reducing dilutive equity funding. Investors hope last week's $10.3 million series D...
01:16 , Jan 20, 2011 |  BC Extra  |  Financial News

Altor raises $10.3M in D round

Altor BioScience Corp. (Miramar, Fla.) raised $10.3 million in a series D round co-led by new investor Florida Growth Fund and Sanderling Ventures, an existing investor. Existing individual investors also participated. Altor's lead cancer candidate...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Clinical News

ALT-801: Preliminary Phase I/II data

Preliminary data from an open-label, dose-escalation, U.S. Phase I/IIa trial (CA-ALT-801-01-06) showed no dose-limiting toxicities in the first cohort of patients receiving 0.015 mg/kg of IV ALT-801. The trial will enroll about 25 patients and...
07:00 , Apr 5, 2004 |  BC Week In Review  |  Clinical News

Altor BioScience preclinical data

TCR-IL-2 inhibited tumor growth and metastasis in an mouse model of melanoma. Data were presented at the American Association for Cancer Research in meeting Orlando. Altor BioScience Corp., Miramar, Fla.   Product: TCR-IL-2   Indication: Treat...